

Jennifer June Brown et al.

Serial No. 10/042,711

Filed: December 12, 2001

Page 2 (Amendment and Response to August 8, 2007 Office Action-- October 29, 2007)

AMENDMENT TO THE CLAIMS

Please replace all listings of the claims with the following:

Claims 1-33 (CANCELLED)

Claims 34-38 (WITHDRAWN)

Claim 39. (CURRENTLY AMENDED) A method for developing a therapeutic procedure in a model animal system comprising the steps of:

- a) infecting ~~a lower primate~~ Tupaia with a human viral pathogen, wherein said pathogen is comprising HCV or a human retrovirus;
- b) carrying out a potential therapeutic procedure to said Tupaia ~~lower primate~~; and
- c) evaluating the effect of said therapeutic procedure on disease manifestations caused by said human viral pathogen.

Claim 40. (CANCELLED)

Claim 41. (CURRENTLY AMENDED) The method of claim 39 wherein said human retrovirus is comprises HIV 1, HIV 2, HTLV-1 or HTLV-2.

Claim 42. (WITHDRAWN)

Claim 43. (PREVIOUSLY PRESENTED) The method of claim 39 wherein said therapeutic procedure comprises oral tolerization.

Claims 44-48. (WITHDRAWN)

ENZ-57(CIP)(C)

Claim 49. (CURRENTLY AMENDED) A method for developing a therapeutic procedure which alleviates clinical manifestations of a disease caused by a human viral pathogen, ~~comprising~~ wherein said pathogen is HCV or a human retrovirus, comprising the steps of:

- a) infecting Tupaia ~~a lower primate~~ with a human viral pathogen, wherein said pathogen is ~~comprising~~ HCV or a human retrovirus;
- b) carrying out a potential therapeutic procedure to said Tupaia ~~lower primate~~; and
- c) evaluating the effect of said therapeutic procedure on clinical manifestations caused by said human viral pathogen.

Claim 50. (PREVIOUSLY PRESENTED) The method of claim 49 wherein said therapeutic procedure comprises oral tolerization.

Claim 51. (PREVIOUSLY PRESENTED) The method of claim 49 wherein said clinical manifestations are secondary disease manifestations of said infection.

Claims 52-57. (WITHDRAWN)

Claim 58. (CURRENTLY AMENDED) A method for developing a therapeutic procedure in a model animal system comprising the steps of:

- a) infecting Tupaia ~~a lower primate~~ with a human viral pathogen;
- b) carrying out a potential therapeutic procedure to said Tupaia ~~lower primate~~; and
- c) evaluating the effect of said therapeutic procedure on secondary disease manifestations caused by said human viral pathogen.

Claim 59. (CANCELLED)

ENZ-57(CIP)(C)

Jennifer June Brown et al.

Serial No. 10/042,711

Filed: December 12, 2001

Page 4 (Amendment and Response to August 8, 2007 Office Action– October 29, 2007)

Claim 60. (CURRENTLY AMENDED) The method of claim 58 wherein said human viral pathogen is ~~comprises~~ a human retrovirus.

Claim 61. (CURRENTLY AMENDED) The method of claim 58 wherein said human retrovirus is ~~comprises~~ HIV 1, HIV 2, HTLV-1 or HTLV-2.

Claim 62. (CURRENTLY AMENDED) The method of claim 58 wherein said human viral pathogen is ~~comprises~~ HBV or HCV.

Claim 63. (PREVIOUSLY PRESENTED) The method of claim 58 wherein said therapeutic procedure comprises oral tolerization.

Claim 64-68. (WITHDRAWN)

Claim 69. (CURRENTLY AMENDED) A method for developing a therapeutic procedure which alleviates secondary clinical manifestations of a disease caused by a human viral pathogen comprising the steps of:

- a) infecting Tupaia ~~a lower primate~~ with a human viral pathogen;
- b) carrying out a potential therapeutic procedure to said Tupaia ~~lower primate~~; and
- c) evaluating the effect of said therapeutic procedure on clinical manifestations caused by said human viral pathogen.

Claim 70. (CANCELLED)

Claim 71. (CURRENTLY AMENDED) The method of claim ~~69~~ 70 wherein said human viral pathogen is ~~comprises~~ a human retrovirus.

ENZ-57(CIP)(C)

Jennifer June Brown et al.

Serial No. 10/042,711

Filed: December 12, 2001

Page 5 (Amendment and Response to August 8, 2007 Office Action– October 29, 2007)

Claim 72. (CURRENTLY AMENDED) The method of claim 71 wherein said human retrovirus is comprises HIV 1, HIV 2, HTLV-1 or HTLV-2.

Claim 73. (CURRENTLY AMENDED) The method of claim 69 wherein said human viral pathogen is comprises HBV or HCV.

Claim 74. (PREVEIOUSLY PRESENTED) The method of claim 69 wherein said therapeutic procedure comprises oral tolerization.

ENZ-57(CIP)(C)